Martingale Asset Management
BEAM icon

Martingale Asset Management’s Beam Therapeutics BEAM Stock Holding History

Martingale Asset Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,038
Closed -$235K – 790
2025
Q1 		$235K Buy
12,038
+600
+5% +$15.7K 0.01% 717
2024
Q4 		$284K Buy
11,438
+909
+9% +$23.2K 0.01% 698
2024
Q3 		$258K Buy
10,529
+1,600
+18% +$41.3K 0.01% 728
2024
Q2 		$209K Buy
+8,929
New +$219K ﹤0.01% 755

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Martingale Asset Management's BEAM Position: Q2 2025 in Review

Martingale Asset Management sold out of Beam Therapeutics (BEAM) in Q2 2025, closing a stake of 12,038 shares — an estimated $235K sold.

Martingale Asset Management first reported a position in BEAM in Q2 2024 and held it in 4 quarters. The position peaked at $284K in Q4 2024. 217 funds tracked by Wall St. Rank hold BEAM as of Q2 2025.

  • Martingale Asset Management reported no remaining Beam Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Martingale Asset Management sold 12,038 Beam Therapeutics shares in Q2 2025, an estimated $235K.
  • Martingale Asset Management first reported a position in Beam Therapeutics in Q2 2024 and held it in 4 quarters.
  • Martingale Asset Management's Beam Therapeutics position peaked at $284K in Q4 2024.
  • 217 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2025.

Based on Martingale Asset Management's 13F filing for Q2 2025, filed 11 Aug 2025.